Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

47.8K
Overview
47.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

552
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
552
Cancer Vaccines01:30

Cancer Vaccines

590
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
590
Cross-reactivity00:42

Cross-reactivity

31.9K
Overview
31.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective mechanism of action of the antifungal drug naftifine against <i>Mycobacterium abscessus</i> infection.

Antimicrobial agents and chemotherapy·2026
Same author

Stress granule component TIA-1 is a negative regulator of the non-canonical NLRP3 inflammasome.

bioRxiv : the preprint server for biology·2025
Same author

A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Dual COVID-19-Flu Mucosal Vaccines.

Small science·2025
Same author

The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice.

Vaccines·2025
Same author

Combination of live attenuated and adenovirus-based vaccines completely protects interferon gamma (IFNγ) knockout mice against pneumonic plague.

bioRxiv : the preprint server for biology·2024
Same author

A bacteriophage cocktail targeting <i>Yersinia pestis</i> provides strong post-exposure protection in a rat pneumonic plague model.

Microbiology spectrum·2024

Related Experiment Video

Updated: Nov 1, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K

Plague vaccines: new developments in an ongoing search.

Jason A Rosenzweig1, Emily K Hendrix2, Ashok K Chopra3

  • 1Department of Biology, Texas Southern University, Houston, TX, 77004, USA. Jason.rosenzweig@tsu.edu.

Applied Microbiology and Biotechnology
|June 18, 2021
PubMed
Summary

Developing effective plague vaccines is critical due to the threat of Yersinia pestis. Research is advancing on DNA, live-attenuated, and subunit vaccine candidates, as no FDA-approved vaccine currently exists.

Keywords:
DNA vaccinesHumoralLive attenuatedProtectionProtein subunit

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.3K
'Bioluminescent' Reporter Phage for the Detection of Category A Bacterial Pathogens
11:31

'Bioluminescent' Reporter Phage for the Detection of Category A Bacterial Pathogens

Published on: July 8, 2011

13.7K

Related Experiment Videos

Last Updated: Nov 1, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.3K
'Bioluminescent' Reporter Phage for the Detection of Category A Bacterial Pathogens
11:31

'Bioluminescent' Reporter Phage for the Detection of Category A Bacterial Pathogens

Published on: July 8, 2011

13.7K

Area of Science:

  • Microbiology and Immunology
  • Vaccinology
  • Infectious Disease Epidemiology

Background:

  • Pandemic threats, such as SARS-CoV-2, highlight the urgent need for vaccines against novel and reemerging pathogens.
  • Yersinia pestis, the plague bacterium, is a significant global health concern responsible for historical pandemics and ongoing outbreaks.
  • The lack of a Food and Drug Administration-licensed plague vaccine in Western nations, coupled with the rise of antibiotic-resistant strains, necessitates accelerated vaccine development.

Purpose of the Study:

  • To review recent advancements in plague vaccine development.
  • To discuss the critical need for a viable plague vaccine in the face of global health challenges.
  • To highlight progress in various vaccine platforms targeting Yersinia pestis.

Main Methods:

  • Review of current scientific literature on plague vaccine research.
  • Analysis of progress in subunit, live-attenuated, and nucleic acid-based vaccine candidates.
  • Examination of Yersinia pestis epidemiology and the challenges in vaccine accessibility.

Main Results:

  • Several promising plague vaccine candidates are under development, including DNA, live-attenuated, and subunit approaches.
  • Recent outbreaks globally underscore the continued relevance and threat of Yersinia pestis.
  • Progress has been made in identifying potential targets and platforms for effective plague vaccines.

Conclusions:

  • Plague vaccine development is an ongoing and critical endeavor, with several promising candidates showing potential.
  • Continued research into diverse vaccine platforms is essential to address the threat of Yersinia pestis and potential antibiotic resistance.
  • The development of a safe and effective plague vaccine is crucial for global public health preparedness.